NDATOPICALCREAMPriority Review
Approved
Nov 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benoquin (monobenzone) is a topical cream depigmenting agent approved in 1952 for treating hyperpigmentation disorders, particularly vitiligo and melasma. The mechanism involves inhibition of melanin synthesis through suppression of tyrosinase activity. It is a small molecule therapeutic applied directly to affected skin areas.
LOE Approaching
As a legacy product nearing loss of exclusivity with moderate competitive pressure (30%), commercial teams may focus on defending market share through physician relationships and patient loyalty rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Benoquin offers limited career growth opportunities given its mature, LOE-approaching lifecycle and minimal linked job openings. Roles focus on maintaining market presence and managing decline rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on BENOQUIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.